Market Overview:
The global oral antidiabetic agents market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising awareness about oral antidiabetic drugs, and technological advancements in the field of diabetes treatment. Based on type, the global oral antidiabetic agents market is segmented into sulfonylureas, meglitinides, biguanides, thiazolidinediones (TZDs), and alpha-glucosidase inhibitors (AGIs). Sulfonylureas are currently the most popular type of oral antidiabetics drugs and are expected to maintain their dominance during the forecast period. However, TZDs are anticipated to witness highest growth rate over the forecast period owing to their ability to improve insulin sensitivity and reduce blood sugar levels effectively. Based on application,the global oral antidiabetic agents market is segmented into home use, medical institutions such as hospitals & clinics., and others including research institutes & pharmaceutical companies. Home use held majority share in 2017 owingto easy availabilityand affordabilityof these drugs as comparedto those available through medical institutions. However,.
Product Definition:
A class of medications used to treat diabetes mellitus by lowering blood sugar levels. Oral antidiabetic agents are taken by mouth and include insulin, sulfonylureas, meglitinides, biguanides, and thiazolidinediones.
Sulfonylureas:
Sulfonylureas are a class of drug used to treat type II diabetes. They work by increasing the sensitivity of the cells to insulin, which in turn increases the amount of glucose that is absorbed into the blood cells. Sulfonylureas were first introduced in Japan and were later marketed around the world under different brand names such as Diabinese and Wytensin.
Meglitinides:
The global meglitinides and its usage in the oral antidiabetic agents market is projected to grow at a lucrative rate during the forecast period. The key drivers for this market are increasing prevalence of diabetes, growing demand for long-acting type 2 diabetes drugs, and favorable regulatory scenarios across regions.
Application Insights:
The others segment held the largest share of more than 60.0% in 2017. The application includes commercial usage as well as non-medical usage of drugs by patients without prescription, which are available over the counter at pharmacies and supermarkets. The other applications include type 2 diabetes mellitus and CVDs such as heart diseases, stroke, blood pressure disorders, and cholesterol levels management.
Medical institutions were the second largest application for antidiabetic agents in 2017 with a market share of 23.4%.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region over the forecast period owing to a large diabetic population base, increasing healthcare expenditure and rising awareness about antidiabetic drugs. In addition, growing penetration of modern oral anti-diabetic agents in China and India on account of regulatory approvals for home use will drive growth during the forecast period.
Europe accounted for more than 30% share in 2016 owing to high incidence rates of diabetes coupled with presence of a large target population base. Moreover, high adoption rate regarding new treatment options such as SUs will boost regional market growth during the estimated time frame. Latin America is also anticipated to witness significant CAGR over the coming years due to rapid economic development along with improving healthcare infrastructure & availability in Brazil & Mexico.
Growth Factors:
- Increasing prevalence of diabetes mellitus: The global prevalence of diabetes is increasing at an alarming rate. This is mainly due to the changing lifestyle and dietary habits of people across the world. As a result, there is an increase in the demand for oral antidiabetic agents.
- Growing awareness about diabetes and its complications: There is growing awareness among people about diabetes and its complications such as heart disease, stroke, kidney failure, etc. This has led to an increase in the demand for oral antidiabetic agents as they help in controlling blood sugar levels effectively.
- Technological advancements in oral antidiabetic drugs: There have been several technological advancements in oral antidiabetic drugs over the past few years which has helped improve their efficacy and safety profile considerably. This has resulted in an increase in their adoption rates worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Antidiabetic Agents Market Research Report
By Type
Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, Alpha-glucosidase Inhibitors
By Application
Home Use, Medical Institutions, Others
By Companies
Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, AstraZeneca, Wockhardt UK, Merck, Pfizer, Cipla
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
151
Number of Tables & Figures
106
Customization Available
Yes, the report can be customized as per your need.
Global Oral Antidiabetic Agents Market Report Segments:
The global Oral Antidiabetic Agents market is segmented on the basis of:
Types
Sulfonylureas, Meglitinides, Biguanides, Thiazolidinediones, Alpha-glucosidase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Home Use, Medical Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Eli Lilly
- Sanofi
- Roche
- Teva
- AstraZeneca
- Wockhardt UK
- Merck
- Pfizer
- Cipla
Highlights of The Oral Antidiabetic Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sulfonylureas
- Meglitinides
- Biguanides
- Thiazolidinediones
- Alpha-glucosidase Inhibitors
- By Application:
- Home Use
- Medical Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Antidiabetic Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral antidiabetic agents are medications that help to lower blood sugar levels. They are taken by mouth (by mouth [by mouth]).
Some of the major companies in the oral antidiabetic agents market are Novo Nordisk, Eli Lilly, Sanofi, Roche, Teva, AstraZeneca, Wockhardt UK, Merck, Pfizer, Cipla.
The oral antidiabetic agents market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Antidiabetic Agents Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oral Antidiabetic Agents Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oral Antidiabetic Agents Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oral Antidiabetic Agents Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oral Antidiabetic Agents Market Size & Forecast, 2018-2028
4.5.1 Oral Antidiabetic Agents Market Size and Y-o-Y Growth
4.5.2 Oral Antidiabetic Agents Market Absolute $ Opportunity
Chapter 5 Global Oral Antidiabetic Agents Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Oral Antidiabetic Agents Market Size Forecast by Type
5.2.1 Sulfonylureas
5.2.2 Meglitinides
5.2.3 Biguanides
5.2.4 Thiazolidinediones
5.2.5 Alpha-glucosidase Inhibitors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Oral Antidiabetic Agents Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Oral Antidiabetic Agents Market Size Forecast by Applications
6.2.1 Home Use
6.2.2 Medical Institutions
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Antidiabetic Agents Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Antidiabetic Agents Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Oral Antidiabetic Agents Analysis and Forecast
9.1 Introduction
9.2 North America Oral Antidiabetic Agents Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Oral Antidiabetic Agents Market Size Forecast by Type
9.6.1 Sulfonylureas
9.6.2 Meglitinides
9.6.3 Biguanides
9.6.4 Thiazolidinediones
9.6.5 Alpha-glucosidase Inhibitors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Oral Antidiabetic Agents Market Size Forecast by Applications
9.10.1 Home Use
9.10.2 Medical Institutions
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Oral Antidiabetic Agents Analysis and Forecast
10.1 Introduction
10.2 Europe Oral Antidiabetic Agents Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Oral Antidiabetic Agents Market Size Forecast by Type
10.6.1 Sulfonylureas
10.6.2 Meglitinides
10.6.3 Biguanides
10.6.4 Thiazolidinediones
10.6.5 Alpha-glucosidase Inhibitors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Oral Antidiabetic Agents Market Size Forecast by Applications
10.10.1 Home Use
10.10.2 Medical Institutions
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Oral Antidiabetic Agents Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Oral Antidiabetic Agents Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Oral Antidiabetic Agents Market Size Forecast by Type
11.6.1 Sulfonylureas
11.6.2 Meglitinides
11.6.3 Biguanides
11.6.4 Thiazolidinediones
11.6.5 Alpha-glucosidase Inhibitors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Oral Antidiabetic Agents Market Size Forecast by Applications
11.10.1 Home Use
11.10.2 Medical Institutions
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Oral Antidiabetic Agents Analysis and Forecast
12.1 Introduction
12.2 Latin America Oral Antidiabetic Agents Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Oral Antidiabetic Agents Market Size Forecast by Type
12.6.1 Sulfonylureas
12.6.2 Meglitinides
12.6.3 Biguanides
12.6.4 Thiazolidinediones
12.6.5 Alpha-glucosidase Inhibitors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Oral Antidiabetic Agents Market Size Forecast by Applications
12.10.1 Home Use
12.10.2 Medical Institutions
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Oral Antidiabetic Agents Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Oral Antidiabetic Agents Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Oral Antidiabetic Agents Market Size Forecast by Type
13.6.1 Sulfonylureas
13.6.2 Meglitinides
13.6.3 Biguanides
13.6.4 Thiazolidinediones
13.6.5 Alpha-glucosidase Inhibitors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Oral Antidiabetic Agents Market Size Forecast by Applications
13.10.1 Home Use
13.10.2 Medical Institutions
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Antidiabetic Agents Market: Competitive Dashboard
14.2 Global Oral Antidiabetic Agents Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Eli Lilly
14.3.3 Sanofi
14.3.4 Roche
14.3.5 Teva
14.3.6 AstraZeneca
14.3.7 Wockhardt UK
14.3.8 Merck
14.3.9 Pfizer
14.3.10 Cipla
